Nitric oxide-assisted mucus-walking zwitterionic nanocomplexes for synergistic treatment of severe respiratory infectious disease

Kyungtae Park, Sungwon Jung, Hye Jin Lee, Hyangsu Nam, Sungeun Heo, Yoogyeong Oh, Chai Won Park, Jungbum Kim, June Hong Ahn, Jong Bum Lee, Patrick T.J. Hwang, Sangmin Lee, Wonhwa Lee, Jinkee Hong

Research output: Contribution to journalArticlepeer-review

Abstract

Among patients who suffer from lung-related disability, acute respiratory distress syndrome (ARDS) is one of the diseases with the significant mortality rate and the main cause is the interference in pulmonary drug delivery by accumulated bronchoalveolar lavage fluid (BALF) in the alveolar region. Here, a zwitterion-functionalized multi-drug nanocomplex (ZnC) capable of anti-mucociliary clearance was synthesized. Additionally, nitric oxide (NO) was functionalized with ZnC to fuel the mobility in the BALF through its role as a nanomotor as well as anti-inflammation. Subsequently, dexamethasone (Dex) was loaded and final product of anti-inflammatory mucus permeator (AIM) was introduced. By in situ tracking the AIM within the mucus-rich environment, the fueled mobility by NO and zwitterion was demonstrated. Notably, when AIM was inhaled by the in vivo ARDS model, there was an increase in the anti-inflammation effect due to the presence of ZnC as well as the synergy between NO and Dex, which recovered the pulmonary function of the model and increased survival rate.

Original languageEnglish
Pages (from-to)57-70
Number of pages14
JournalMaterials Today
Volume72
DOIs
StatePublished - Jan 2024

Keywords

  • Acute respiratory distress syndrome
  • Anti-inflammation
  • Mobility in mucus
  • Nitric oxide nanomotor
  • Zwitterion

Fingerprint

Dive into the research topics of 'Nitric oxide-assisted mucus-walking zwitterionic nanocomplexes for synergistic treatment of severe respiratory infectious disease'. Together they form a unique fingerprint.

Cite this